Celcuity, Inc. research snapshot
CELC AI stock analysis currently sees Celcuity as a pre-commercial biotechnology company developing gedatolisib, a pan-PI3K/mTOR inhibitor, for HR+/HER2- advanced breast cancer and other solid tumors. Positive Phase 3 VIKTORIA-1 data for PIK3CA mutant advanced breast cancer were reported in June 2026, and the VIKTORIA-2 trial was expanded to include endocrine-sensitive breast cancer patients. At the July 12, 2026 cutoff, CELC traded near $107.58 with a verified market capitalization of $5.25 billion. The core tension is that Phase 3 data are positive and the target indication has a large addressable patient population, while the company has zero product revenue, a trailing twelve-month net loss of approximately $177 million, widening cash burn, a $500 million convertible note offering completed in June 2026, and substantial debt. This page is informational only and not investment advice.
Current price
$107.58
Market cap
$5.25 billion
AI score
35 / 100
Rating
Gedatolisib Phase 3 data from VIKTORIA-1 were positive, but the company remains pre-revenue with binary regulatory and commercial risk
Trend status
Below the 50-day moving average, well above the 200-day moving average and 52-week low, near the lower end of the 52-week range
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Celcuity is a pre-revenue precision oncology company developing gedatolisib for HR+/HER2- advanced breast cancer and other solid tumors. The business quality is unproven: no approved products, no revenue, and no commercial infrastructure yet. Clinical execution with VIKTORIA-1 has been positive, but business quality cannot be assessed without a commercial track record. | Low |
| Moat | The moat is hypothetical. Gedatolisib is a pan-PI3K/mTOR inhibitor that has shown efficacy in PIK3CA mutant breast cancer, differentiating it from alpha-specific PI3K inhibitors like alpelisib. If approved, patents, regulatory exclusivity, and manufacturing know-how could create barriers. However, the moat is narrow until commercial scale is achieved and competition from other PI3K and CDK4/6 inhibitor combinations is managed. | Low |
| Management | CEO David Dalvey and the management team have guided gedatolisib through Phase 3 success in VIKTORIA-1. The next capital-allocation test is managing the $500 million convertible note due 2032, funding the commercial launch, and advancing the pipeline without excessive further dilution. | Medium |
| Financial trend | CELC has zero revenue and a widening net loss trajectory: -$64 million in FY2023, -$112 million in FY2024, -$177 million in FY2025, and a -$53 million loss in Q1 2026 alone. Operating cash burn was -$55 million in Q1 2026. The trend is deteriorating and will continue until product revenue begins. | High |
| Valuation | At $107.58, CELC has a $5.25 billion market cap with zero revenue and negative earnings. P/E and P/S are not meaningful. P/B is 49.58x, reflecting the market pricing future commercial cash flows rather than current book value. Net cash of approximately $64 million after the $500 million convertible note issuance provides limited runway. | Medium |
| Technical trend | CELC was trading at $107.58, within the lower half of its 52-week range of $13.35 to $151.02. The stock is well above its 52-week low but below the 50-day moving average, indicating a pullback from the high of $151.02 reached in early 2026 following positive trial data. | Medium-high |
| Risk level | Risk is very high. CELC faces binary regulatory decisions, commercial launch execution, pricing and reimbursement uncertainty, competition from approved PI3K and CDK4/6 inhibitor therapies, significant debt ($323M in long-term debt plus $500M in convertible notes), cash burn, potential dilutive financing, and clinical-stage pipeline risk. | High |
| AI confidence | Reported financial and clinical data are well documented, but AI cannot know FDA decisions, pricing, market adoption, or the outcome of future trials. | High data confidence |
| Investment certainty | Investment certainty is low because the entire valuation depends on regulatory approval and commercial adoption of a drug that has not yet been approved or sold. The wide range of analyst price targets ($110 to $171) illustrates the uncertainty. | Low |
CELC AI stock forecast
The CELC AI stock forecast uses scenarios instead of a promised price. Because CELC is pre-revenue with no positive EPS, the forecast uses analyst price targets and illustrative peak sales assumptions for gedatolisib in HR+/HER2- advanced breast cancer. These scenarios are valuation frameworks, not predictions, because FDA decisions, pricing, market share, and competition remain highly uncertain.
$150 to $175
More likely if gedatolisib is approved in PIK3CA mutant advanced breast cancer with a broad label in 2027, commercial launch execution is strong, pricing supports meaningful peak sales, the VIKTORIA-2 trial expands the addressable market, and the company manages its debt load without dilutive financing.
$100 to $130
More likely if gedatolisib is approved with a moderate label, initial commercial uptake is steady but not exceptional, competition from alpelisib and other PI3K inhibitors limits market share, and ongoing cash burn requires additional financing.
$40 to $70
More likely if a Complete Response Letter or significant label limitation delays or restricts approval, pricing or reimbursement disappoints, competition captures more share than expected, or the $500 million convertible note and cash burn force dilutive financing or debt restructuring.
CELC AI technical analysis
CELC AI technical analysis uses the July 10, 2026 MarketBeat market snapshot. The static page does not fetch live market data. The price reference of $107.58 was below the 50-day moving average but above the 200-day moving average, indicating a pullback within a longer-term uptrend.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $107.58 | Quote snapshot used for the July 12, 2026 analysis and market-cap calculation. |
| Near resistance | $120 to $125 | The 50-day moving average area. A live chart should confirm reclaiming this level as a positive signal. |
| Secondary resistance | $140 to $145 | The area between the 200-day moving average and prior support that predates the VIKTORIA-1 rally. |
| 52-week high resistance | $151.02 | The all-time high reached after the VIKTORIA-1 positive data. A sustained breakout above this level would open a new price range. |
| Near support | $95 to $100 | The psychological $100 level and recent price consolidation zone. |
| Secondary support | $75 to $85 | The pre-data rally support zone. This area held before the VIKTORIA-1 runup. |
| Momentum | RSI near 35-40 | MarketBeat reported the stock pulling back from highs. RSI may be in neutral to slightly oversold territory, suggesting mean reversion potential. |
| Volume | 1.14 million average shares | MarketBeat reported 30-day average volume of 1.14 million shares. Volume spikes around clinical data readouts and financing events. |
| Volatility | Beta 0.16, event-driven | Reported beta was low, but binary biotech events can produce sharp gaps that beta does not capture. |
| Short interest | 25.95% of float | Short interest is extremely elevated at 25.95%, reflecting significant bearish positioning. This can add volatility around binary events and create short-squeeze potential. |
| Invalidation | Sustained close below $95 | A sustained close below the $95-$100 support zone would weaken the technical picture and should trigger a review of fundamentals. |
CELC AI trading strategy
The CELC AI trading strategy is a research and risk-control framework, not a personalized recommendation. It combines live chart confirmation with clinical trial milestones, regulatory updates, cash position changes, debt management, and financing announcements.
CELC is driven by binary clinical and regulatory events. Key catalysts include VIKTORIA-2 trial data updates, regulatory submissions for gedatolisib, FDA review milestones, and commercial launch preparation announcements.
Binary event risk means position sizing must account for the possibility of 30-50% gap moves in either direction. Tight stops are unreliable around clinical data readouts and regulatory decisions.
If CELC reclaims the 50-day moving average near $120-$125 and holds above $100 support, a trend-following approach can be considered. Confirm price action with positive clinical or regulatory progress and no deterioration in cash position.
A sustained close below $95 or a failed clinical/regulatory event would invalidate the trend. Size for gap risk rather than relying on a tight stop.
Track VIKTORIA-2 trial enrollment and data timelines, regulatory submission progress for gedatolisib, FDA labeling decisions, cash and investment balance, operating burn rate, convertible note conversion activity, any new equity or debt financing, pricing expectations in target indications, and competitor developments from alpelisib and other PI3K inhibitors.
Reduce confidence if cash burn accelerates without a corresponding increase in near-term approval probability, if the FDA issues a CRL or significant clinical hold, if the convertible note conversion dilutes existing shareholders substantially, or if competition limits pricing potential.
Investment research summary
Celcuity is a pre-commercial precision oncology company developing gedatolisib, a pan-PI3K/mTOR inhibitor, for HR+/HER2- advanced breast cancer and other solid tumors. Customers and payers will pay if the drug is approved, gains favorable labeling for PIK3CA mutant breast cancer, achieves broad reimbursement, and demonstrates superior efficacy versus existing therapies such as alpelisib plus fulvestrant.
The moat is potential rather than proven. If approved, gedatolisib would benefit from regulatory exclusivity, patent protection, and differentiated pan-PI3K/mTOR inhibition that may offer advantages over alpha-specific PI3K inhibitors. The moat can narrow if competing PI3K inhibitors, improved CDK4/6 combinations, or novel therapies enter the market.
The thesis fails if the FDA issues a Complete Response Letter, if the label is significantly narrower than expected, if pricing or reimbursement is unfavorable, if the $500 million convertible note creates financial strain, if commercial launch execution is slow, if competition from alpelisib or other therapies erodes market share, if cash burn requires dilutive financing, or if pipeline candidates fail in clinical trials.
Management has advanced gedatolisib through Phase 3 success in VIKTORIA-1 and expanded the VIKTORIA-2 trial. The capital-allocation test ahead is managing $323 million in long-term debt plus $500 million in convertible notes, funding commercial launch investment, R&D spending, and the VIKTORIA-2 expansion while minimizing further shareholder dilution. Insider selling of $4.78 million in the past three months warrants monitoring.
Precision oncology and targeted therapy for HR+/HER2- advanced breast cancer represent a lasting industry trend. The PIK3CA mutant subset affects approximately 40% of HR+/HER2- breast cancer patients, creating a large addressable market. However, the space is competitive with alpelisib already approved and several next-generation PI3K inhibitors in development.
The market is pricing CELC at $5.25 billion based on expected future approval and commercial cash flows rather than current earnings or revenue. Margin of safety is limited until approval, label, pricing, and initial commercial data provide concrete evidence of the revenue trajectory. The $110 lowest analyst price target suggests limited downside protection at current levels.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CELC price | $107.58 | MarketBeat quote snapshot | July 12, 2026 |
| Market capitalization | $5.25 billion, verified as $107.58 x 48.77 million shares | financial_rigor.py and MarketBeat | July 12, 2026 |
| Cash and cash equivalents | $145 million at March 31, 2026 | MarketBeat financials (balance sheet) | July 12, 2026 |
| Short-term investments | $242 million at March 31, 2026 | MarketBeat financials (balance sheet) | July 12, 2026 |
| Long-term debt | $323 million at March 31, 2026 (before June 2026 $500M convertible note) | MarketBeat financials (balance sheet) | July 12, 2026 |
| FY2025 net loss | -$177 million, widening from -$112 million in FY2024 | MarketBeat financials (income statement) and SEC filings | July 12, 2026 |
| Q1 2026 net loss | -$53 million; operating cash use -$55 million | MarketBeat financials (cash flow statement) | July 12, 2026 |
| Shares outstanding | 48.77 million at March 31, 2026 | MarketBeat financials | July 12, 2026 |
| Valuation math | P/E and P/FCF are not meaningful with negative TTM EPS and free cash flow; P/B about 49.58x; ROE -244.61% | financial_rigor.py valuation verification | July 12, 2026 |
| Technical inputs | 52-week range $13.35 to $151.02, average volume 1.14M, short interest 25.95% of float, beta 0.16 | MarketBeat statistics | July 12, 2026 |
| Analyst consensus | Moderate Buy, 12 analysts, price target range $110.00 to $171.00, consensus $152.09 | MarketBeat analyst forecasts | July 12, 2026 |
This CELC AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, clinical trial disclosures, quote snapshots, technical data, and third-party sources as of July 12, 2026. They may be wrong, incomplete, or outdated after new clinical data, FDA decisions, commercial updates, financing events, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
